{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:55:45Z","timestamp":1791633345173,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.053","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:02:34Z","timestamp":1729566154000},"page":"163-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["From the first pilot initiatives in the early 1990s to the national OSIAP survey in the 2020s: More than 30 years of insight in medication diversion phenomenon in France"],"prefix":"10.1016","volume":"80","author":[{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Jouanjus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.053_bib0320","first-page":"15","article-title":"The French system of evaluation of dependence: establishment in a legal system","volume":"56","author":"Baumevieille","year":"2001","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0325","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3917\/psyt.191.0065","article-title":"Addiction m\u00e9dicamenteuse\u00a0: quelles donn\u00e9es pour \u00e9valuer et pr\u00e9venir\u00a0?","volume":"19","author":"Lapeyre-Mestre","year":"2013","journal-title":"Psychotropes"},{"key":"10.1016\/j.therap.2024.10.053_bib0330","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0335","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14659891.2023.2213325","article-title":"Misuse of psychoactive medicines and its consequences in the European Union\u00a0\u2013\u00a0a scoping review","volume":"29","author":"Carmona Ara\u00fajo","year":"2024","journal-title":"J Subst Use"},{"key":"10.1016\/j.therap.2024.10.053_bib0340","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2010.00882.x","article-title":"Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network","volume":"25","author":"Frauger","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0345","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000346179","article-title":"Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France","volume":"19","author":"Peyriere","year":"2013","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.10.053_bib0350","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2515\/therapie\/2015012","article-title":"Example of an investigation of an \u201cemergent\u201d phenomenon in addiction vigilance: the case of methylphenidate","volume":"70","author":"Micallef","year":"2015","journal-title":"Therapie"},{"issue":"Suppl 5S","key":"10.1016\/j.therap.2024.10.053_bib0355","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.2515\/therapie\/2015048","article-title":"\u00c9valuation du potentiel d\u2019abus et de d\u00e9pendance de la qu\u00e9tiapine (Xeroquel\u00ae)","volume":"78","author":"Peyri\u00e8re","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0360","doi-asserted-by":"crossref","first-page":"639780","DOI":"10.3389\/fpsyt.2021.639780","article-title":"Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2024.10.053_bib0365","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0370","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.therap.2023.02.002","article-title":"Alprazolam misuse: analysis of French Addictovigilance Network data from 2011 to 2020","volume":"78","author":"Diaz","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0375","first-page":"9","article-title":"Aspects of social pharmacology","volume":"22","author":"Venulet","year":"1978","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.therap.2024.10.053_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00048678109159402","article-title":"Benzodiazepines\u00a0\u2013\u00a0panacea or poison?","volume":"15","author":"Lader","year":"1981","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.therap.2024.10.053_bib0385","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0376-8716(86)90063-3","article-title":"Relative abuse of diazepam and oxazepam: prescription forgeries and theft\/loss reports in Sweden","volume":"16","author":"Bergman","year":"1986","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.053_bib0390","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF00637747","article-title":"Use of prescription forgeries in a drug abuse surveillance network","volume":"36","author":"Bergman","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0395","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3917\/psyt.103.0131","article-title":"La Commission nationale des stup\u00e9fiants et des psychotropes. Historique et actualit\u00e9","volume":"10","author":"Dugarin","year":"2004","journal-title":"Psychotropes"},{"key":"10.1016\/j.therap.2024.10.053_bib0400","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2016.05.001","article-title":"Twenty-five years of the French Addictovigilance Network (FAN)","volume":"71","author":"Micallef","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0405","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.therap.2018.07.007","article-title":"From psychoactive medicines to addictovigilance in French Public Health Code (1990\u20132017)","volume":"74","author":"Baumevieille","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0410","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0415","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.03.009","article-title":"Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France","volume":"126","author":"Pauly","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.053_bib0420","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/eurpub\/ckad003","article-title":"French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change","volume":"33","author":"Aquizerate","year":"2023","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.therap.2024.10.053_bib0425","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002280050246","article-title":"Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyr\u00e9n\u00e9es","volume":"52","author":"Lapeyre-Mestre","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0430","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/106002809703100706","article-title":"Abuse of prescription medicines in Southwestern France","volume":"31","author":"Baumevieille","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2024.10.053_bib0435","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00228-001-0412-7","article-title":"Forged medical prescriptions in a community pharmacy network in Midi-Pyr\u00e9n\u00e9es area: assessment of a falsification ratio","volume":"57","author":"Llau","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0440","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00002018-200730030-00007","article-title":"Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey","volume":"30","author":"Boeuf","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.053_bib0445","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0450","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.therap.2021.01.027","article-title":"Ordonnances suspectes indicateur d\u2019abus possible\u00a0: r\u00e9sultats de l\u2019enqu\u00eate OSIAP 2019","volume":"76","author":"Jouanjus","year":"2021","journal-title":"Therapie"},{"issue":"S1","key":"10.1016\/j.therap.2024.10.053_bib0455","first-page":"61","article-title":"Analysis of oxycodone misuse, abuse and dependence in France in the last decade: results from the French Addictovigilance Network. Discussed Poster Abstracts\u00a0\u2013\u00a0PM1","volume":"38","author":"Jalles","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0460","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/bcp.15052","article-title":"Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France","volume":"88","author":"Jouanjus","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0465","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0470","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.therap.2022.10.037","article-title":"Impact de la modification des r\u00e8gles de prescription de la pr\u00e9gabaline dans l\u2019Est de la France","volume":"77","author":"Patenotte","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0475","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3917\/psyt.191.0065","article-title":"Addiction m\u00e9dicamenteuse\u00a0: quelles donn\u00e9es pour \u00e9valuer et pr\u00e9venir\u00a0?","volume":"19","author":"Lapeyre-Mestre","year":"2013","journal-title":"Psychotropes"},{"key":"10.1016\/j.therap.2024.10.053_bib0480","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.genhosppsych.2013.04.013","article-title":"Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy","volume":"35","author":"Bersani","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.therap.2024.10.053_bib0485","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/hup.2481","article-title":"Injecting eye-drops: a mini-review on the non-clinical use of tropicamide","volume":"30","author":"Bersani","year":"2015","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0490","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/08897077.2014.924465","article-title":"Intravenous abuse of tropicamide in opioid use disorder: presentation of 2 cases","volume":"36","author":"Bozkurt","year":"2015","journal-title":"Subst Abuse"},{"key":"10.1016\/j.therap.2024.10.053_bib0495","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/ijp.IJP_635_19","article-title":"Tropicamide abuse and regulatory measures in a Sudanese hospital","volume":"52","author":"Eltom","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0500","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/WNF.0b013e31828da20e","article-title":"Polydrug abuse by intravenous use of heroin and tropicamide-containing eyedrops","volume":"36","author":"Spagnolo","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0505","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/bcp.13272","article-title":"Early signal of diverted use of tropicamide eye drops in France","volume":"83","author":"Ponte","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0510","first-page":"522","article-title":"Abuse of tropicamide eye drops: review of clinical data","volume":"44","author":"Bellman","year":"2022","journal-title":"Braz J Psychiatry"},{"key":"10.1016\/j.therap.2024.10.053_bib0515","first-page":"228","article-title":"Tropicamide-induced psychosis in the context of chemsex practices treated in an emergency department","volume":"36","author":"Sorroche","year":"2024","journal-title":"Emergencias"},{"key":"10.1016\/j.therap.2024.10.053_bib0520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugpo.2015.09.007","article-title":"Misuse of non-prescription codeine containing products: recommendations for detection and reduction of risk in community pharmacies","volume":"27","author":"Van Hout","year":"2016","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2024.10.053_bib0525","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/pds.4624","article-title":"Detecting the diverted use of psychoactive drugs by adolescents and young adults: a pilot study","volume":"27","author":"Jouanjus","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.053_bib0530","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40264-021-01143-2","article-title":"Sales of over-the-counter products containing codeine in 31 countries, 2013\u20132019: a retrospective observational study","volume":"45","author":"Richards","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.053_bib0535","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00044011-200222060-00008","article-title":"Use of codeine and non-codeine cough suppressants","volume":"22","author":"Olivier","year":"2002","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2024.10.053_bib0540","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2515\/therapie:2004093","article-title":"Neocodion misuse: evolution between 1992 and 2002","volume":"59","author":"Armand","year":"2004","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0545","first-page":"35","article-title":"Opioid cough suppressants: update addictovigilance data","volume":"36","author":"Gibaja","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0550","first-page":"32","article-title":"Medical prescription falsified by the patients: analysis of the data recorded in the OSIAP Programme in 2021","volume":"37","author":"Jouanjus","year":"2023","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0555","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0560","first-page":"161","article-title":"Trends in pregabalin, gabapentin and duloxetine use in France after regulatory change on pregabalin prescribing","volume":"37","author":"Cifuentes-Castro","year":"2023","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0565","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000356812","article-title":"A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions","volume":"20","author":"Lapeyre-Mestre","year":"2014","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.10.053_bib0570","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.3390\/ijerph18157818","article-title":"Evaluation of medicine abuse trends in community pharmacies: the Medicine Abuse Observatory (MAO) in a Region of Southern Europe","volume":"18","author":"Perell\u00f3","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2024.10.053_bib0575","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.sapharm.2019.01.016","article-title":"Ophthalmic drug abuse: an observational study from community pharmacies","volume":"15","author":"Al-Khalaileh","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.therap.2024.10.053_bib0580","doi-asserted-by":"crossref","first-page":"997342","DOI":"10.3389\/fphar.2022.997342","article-title":"Community pharmacists\u2019 views and experiences toward over-the-counter medicines misuse and abuse in Saudi Arabia: a qualitative study","volume":"13","author":"Algarni","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0585","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.therap.2019.12.006","article-title":"Community pharmacists, students in pharmacy, and requests of codeine-based medicines: observational study","volume":"75","author":"Baumevieille","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.053_bib0590","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.drugpo.2019.10.010","article-title":"Supply of codeine combination analgesics from Australian pharmacies in the context of voluntary real-time recording and regulatory change: a simulated patient study","volume":"74","author":"Collins","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.therap.2024.10.053_bib0595","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.japh.2021.08.018","article-title":"Development and validation of patient-community pharmacist encounter toolkit regarding substance misuse: Delphi procedure","volume":"62","author":"Fatani","year":"2022","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.therap.2024.10.053_bib0600","doi-asserted-by":"crossref","first-page":"8600","DOI":"10.3390\/ijerph19148600","article-title":"Creation and Implementation of a New Sentinel Surveillance Model in Pharmacy Offices in Southern Europe","volume":"19","author":"Jambrina","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2024.10.053_bib0605","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3390\/ijerph17041334","article-title":"Knowledge, attitudes, and beliefs regarding drug abuse and misuse among community pharmacists in Saudi Arabia","volume":"17","author":"Mobrad","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2024.10.053_bib0610","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.sapharm.2018.02.004","article-title":"An opioid dispensing and misuse prevention algorithm for community pharmacy practice","volume":"15","author":"Rickles","year":"2019","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.therap.2024.10.053_bib0615","doi-asserted-by":"crossref","first-page":"e76499","DOI":"10.1371\/journal.pone.0076499","article-title":"Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in France","volume":"8","author":"Roussin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2024.10.053_bib0620","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s11096-015-0166-4","article-title":"Role of community pharmacists in the detection of potentially inappropriate benzodiazepines prescriptions for insomnia","volume":"37","author":"Urru","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.therap.2024.10.053_bib0625","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bcp.14548","article-title":"Nature and frequency of prescription modifications in community pharmacies: a nationwide study in the Netherlands","volume":"87","author":"van Loon","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.053_bib0630","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101014","article-title":"Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review","volume":"4","author":"Gentile","year":"2020","journal-title":"BJGP Open"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:46:57Z","timestamp":1762220817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001690"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.053","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From the first pilot initiatives in the early 1990s to the national OSIAP survey in the 2020s: More than 30years of insight in medication diversion phenomenon in France","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}